KOHJIN BIO CO LTD (177A.T)
JPY 1703.0
(-0.12%)
JPY 1703.0
(-0.12%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.24 Billion JPY | 4.17% |
| 2022 | 3.11 Billion JPY | -7.74% |
| 2021 | 3.37 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 3.24 Billion JPY | 4.17% |
| 2023 Q4 | 3.24 Billion JPY | 3.28% |
| 2023 Q3 | 3.14 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -5020.452% |
| GNI Group Ltd. | 26.34 Billion JPY | 87.674% |
| Linical Co., Ltd. | 10.3 Billion JPY | 68.491% |
| Trans Genic Inc. | 3.81 Billion JPY | 14.835% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -450.137% |
| Soiken Holdings Inc. | 697.02 Million JPY | -365.828% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | -7.488% |
| AnGes, Inc. | 2.78 Billion JPY | -16.404% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -532.182% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 96.408% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -819.105% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -96.797% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -587.392% |
| CanBas Co., Ltd. | 91.98 Million JPY | -3429.732% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -196.901% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -300.94% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -446.869% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 23.675% |
| PeptiDream Inc. | 29.11 Billion JPY | 88.848% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -473.156% |
| Ribomic Inc. | 155.8 Million JPY | -1983.917% |
| SanBio Company Limited | 2.25 Billion JPY | -43.995% |
| Healios K.K. | 11.28 Billion JPY | 71.23% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -1192.213% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -779.927% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -1244.501% |
| StemRIM | 187 Million JPY | -1636.326% |
| CellSource Co., Ltd. | 677.73 Million JPY | -379.083% |
| FunPep Company Limited | 189.32 Million JPY | -1615.012% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -443.915% |
| Stella Pharma Corporation | 1.44 Billion JPY | -124.917% |
| TMS Co., Ltd. | 97.68 Million JPY | -3223.742% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -3448.79% |
| Cuorips Inc. | 200.96 Million JPY | -1515.702% |
| K Pharma,Inc. | 209.13 Million JPY | -1452.56% |
| Takara Bio Inc. | 11.42 Billion JPY | 71.568% |
| ReproCELL Incorporated | 741.03 Million JPY | -338.163% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -253.807% |
| StemCell Institute Inc. | 3.85 Billion JPY | 15.674% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -257.422% |
| CellSeed Inc. | 301.04 Million JPY | -978.546% |